close
Drug Safety: Managing Innovation in Rheumatology, An Issue of Rheumatic Disease Clinics | Zookal Textbooks | Zookal Textbooks
  • Author(s) Jack Cush; Kathryn Dao
  • Edition
  • Published11152012
  • PublisherElsevier Health Sciences (US)
  • ISBN9781455750597
Edited by Drs. Jack Cush and Kathryn Dao, this issue of Rheumatic Disease Clinics of North America addresses one of the most significant issues facing the rheumatologist today––drug safety in a changing world where rheumatoid arthritis (RA) severity is less, patients are being identified and treated at a very early stage, and prevention is on the horizon. Topics covered include: communicating the risk of side effects, urate-lowering therapies, biphosphonates, biologics, malignancy risks, and administering therapies to patients with co-morbidities.

Drug Safety: Managing Innovation in Rheumatology, An Issue of Rheumatic Disease Clinics

Format
Get it instantly

Zookal account needed

$138.71 $145.95 Save $7.24
Add Zookal Study FREE trial and save a further 0% 

NEW PRICE

$138.71 + free shipping

(0% off - save $0.00)

Zookal Study Free trial

-day FREE trial. $19.95/mo after. Cancel anytime.

*Discount will apply at checkout.

 See terms and conditions

You will get a further 0% off for this item ($138.71 after discount) because you have added Zookal Study Premium Free Trial to your bag.

For this discount to apply, you will need to complete checkout with the Zookal Study Premium Free Trial in your bag.

-
+
  • Author(s) Jack Cush; Kathryn Dao
  • Edition
  • Published11152012
  • PublisherElsevier Health Sciences (US)
  • ISBN9781455750597
Edited by Drs. Jack Cush and Kathryn Dao, this issue of Rheumatic Disease Clinics of North America addresses one of the most significant issues facing the rheumatologist today––drug safety in a changing world where rheumatoid arthritis (RA) severity is less, patients are being identified and treated at a very early stage, and prevention is on the horizon. Topics covered include: communicating the risk of side effects, urate-lowering therapies, biphosphonates, biologics, malignancy risks, and administering therapies to patients with co-morbidities.
translation missing: en.general.search.loading